Sweden· SE-20200115000016
Upstaza 280 miljarder vektorgenom/0,5 ml Infusionsvätska, lösning
A medicinal product containing eladocagene exuparvovec, registered in Sweden by PTC Therapeutics International Limited.
Checked against Swedish Medical Products Agency (Sweden) on
Informational only — not a medical device.
The record
At a glance
Swedish Medical Products Agency (Sweden)- Active substance
- Eladocagene Exuparvovec
- Manufacturer
- PTC Therapeutics International Limited
- Country
- Sweden (SE)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- Swedish Medical Products Agency (Sweden)
- Last checked
- October 1, 2026
Packs & prices · 1
- se_varunummer20200115000016
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Eladocagene exuparvovec in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesKEBILIDIPTC Therapeutics, Inc.
- CzechiaUPSTAZAPTC Therapeutics International Limited, Dublin 2
- SpainUPSTAZA 2,8 × 10E11 GENOMAS VECTORIALES (VG)/0,5 ML PARA SOLUCION PARA PERFUSIONPtc Therapeutics International Limited
- FinlandUpstazaPTC Therapeutics International limited
- FranceUPSTAZA 2,8 x 100 000 000 000 génomes de vecteur (vg)/0,5 mL, solution pour perfusionPTC THERAPEUTICS INTERNATIONAL (IRLANDE)
- BelgiumUpstaza 2.8 10*11 vg/0.5 mlPTC Therapeutics International
- IrelandUpstaza 2.8 × 10^11 vector genomes/0.5 mL solution for infusionPTC Therapeutics International Limited
- IcelandUpstazaPTC Therapeutics International Limited*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Upstaza
- Liechtenstein · Upstaza
- Norway · Upstaza
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swedish Medical Products Agency (Sweden). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d107a8a7-e6ba-44a3-a64e-7a8564f96b07 GET /v1/drugs/d107a8a7-e6ba-44a3-a64e-7a8564f96b07?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "lakemedelsverket",
"doc_types": [
"Dispensbeslut",
"EPAR",
"EMA"
],
"se_npl_id": "20200115000016",
"product_page": "https://www.lakemedelsverket.se/sv/sok-lakemedelsfakta/lakemedel?id=20200115000016",
"product_doc_link": "https://docetp.mpa.se/LMF/Upstaza%2C%20injektionsflaska%2C%201%20st%2C%20sammanfattning%20av%20beslut%2C%20giltigt%20fr.o.m.%202025-05-28%20t.o.m.%202027-05-28_09001bee84a5a16c.pdf"
}See everything about eladocagene exuparvovec.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.